Therapeutic Efficacy and Safety of Kang-Ai Injection Combined with Platinum-Based Doublet Chemotherapy in Advanced NSCLC: A Meta-Analysis

This meta-analysis evaluated the therapeutic efficacy and safety of Kang-ai injection (KA) combined with platinum-based doublet chemotherapy (PBDC) in treating advanced non-small cell lung cancer (NSCLC). Analyzing 30 randomized controlled trials with 1956 patients, the study found that KA combined with PBDC significantly improved tumor response, Karnofsky Performance Scale (KPS) scores, and immune functions (CD3+, CD4+, NK cells, and CD4+/CD8+ ratio) compared to PBDC alone. Additionally, the combination therapy reduced adverse reactions such as gastrointestinal issues, myelosuppression, and hair loss. Despite the small sample size and study limitations, the results suggested that KA combined with PBDC, particularly the NP regimen, could be a beneficial treatment strategy for advanced NSCLC. Further large-scale, rigorous randomized controlled trials were recommended to confirm these findings.